Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Atomoxetine/d · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | JNJ-31001074 1 mg/d 1-mg capsule once daily for 42 days |
| 002 | EXPERIMENTAL | JNJ-31001074 3 mg/d 3-mg capsule once daily for 42 days |
| 003 | EXPERIMENTAL | JNJ-31001074 10 mg/d 10-mg capsule once daily for 42 days |
| 004 | ACTIVE_COMPARATOR | Atomoxetine 80 mg/d 40-mg capsule for 3 days followed by 80-mg capsule once daily for 39 days |
| 005 | ACTIVE_COMPARATOR | OROS methylphenidate HCl 54 mg/d 36-mg capsule for 3 days followed by 54-mg capsule once daily for 39 days |
| 006 | PLACEBO_COMPARATOR | Placebo capsule once daily for 42 days |
| Name | Type | Description |
|---|---|---|
| Atomoxetine 80 mg/d | DRUG | 40-mg capsule for 3 days, followed by 80-mg capsule once daily for 39 days |
| Placebo | DRUG | Placebo capsule once daily for 42 days |
| OROS methylphenidate HCl 54 mg/d | DRUG | 36-mg capsule for 3 days, followed by 54-mg capsule once daily for 39 days |
| JNJ-31001074 3 mg/d | DRUG | 3-mg capsule once daily for 42 days |
| JNJ-31001074 1 mg/d | DRUG | 1-mg capsule once daily for 42 days |
| JNJ-31001074 10 mg/d | DRUG | 10-mg capsule once daily for 42 days |
Inclusion Criteria: * Patients diagnosed with ADHD, confirmed with the Conners Adult ADHD Diagnostic Interview for Diagnostic and Statistical Manual, 4th edition (DSM-IV) (CAADID) * Patients who meet the cutoff scores for the Conners Adult ADHD Rating Scale (CAARS-S:SV) * Patients with a Clinical G...
Atomoxetine/d is an investigational small molecule being studied for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Atomoxetine/d is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker symbol JNJ. The drug is currently in Phase 2 clinical trials for Attention Deficit Hyperactivity Disorder.
Atomoxetine/d is in Phase 2 clinical development. It is an investigational drug for Attention Deficit Hyperactivity Disorder and has not yet received regulatory approval. One Phase 2 trial has been completed.
Atomoxetine/d has one completed clinical trial, NCT00880217, which evaluated three different doses of JNJ-31001074 in adults with Attention Deficit Hyperactivity Disorder. The trial was a randomized, double-blind, placebo-controlled study with 430 participants in the United States.
Yes, Atomoxetine/d is also known as JNJ-31001074. The clinical trial NCT00880217, which studied the drug for Attention Deficit Hyperactivity Disorder, refers to it by this alternative name.